Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy By Ogkologos - September 28, 2026 58 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TAISHAN-302 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR Can Age Affect Response to Immune Checkpoint Inhibitors? July 6, 2018 Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ January 8, 2025 FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer September 19, 2025 COVID-19, Cancer, and Uncertainty: An Oncologist’s Perspective on Coping November 17, 2020 Load more HOT NEWS Estimate of the Global Economic Cost of the Most Prevalent Cancers... CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed Reunión anual de la American Society of Clinical Oncology de 2023:...
